BCL2 and cancer: In addition, some cancer cells can develop resistance to recombinant TRAIL therapy by reducing TRAIL death receptors, overexpression of decoy receptors, antiapoptotic proteins such as c-FLIP and Bcl-2 family members, and decreasing proapoptotic factors [11]; however, the DR5 receptor can activate pro-survival signals in cancer cells [12].